SK44094A3 - Method and composition for determining the immunological activity of bioactive substances - Google Patents

Method and composition for determining the immunological activity of bioactive substances Download PDF

Info

Publication number
SK44094A3
SK44094A3 SK440-94A SK44094A SK44094A3 SK 44094 A3 SK44094 A3 SK 44094A3 SK 44094 A SK44094 A SK 44094A SK 44094 A3 SK44094 A3 SK 44094A3
Authority
SK
Slovakia
Prior art keywords
ttp
pbl
cultures
tested
cytokines
Prior art date
Application number
SK440-94A
Other languages
English (en)
Slovak (sk)
Inventor
Anna Inglot
Zofia Blach-Olszewska
Original Assignee
Torf Ets
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torf Ets filed Critical Torf Ets
Publication of SK44094A3 publication Critical patent/SK44094A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/10—Peat; Amber; Turf; Humus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SK440-94A 1991-10-26 1992-09-28 Method and composition for determining the immunological activity of bioactive substances SK44094A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91118269A EP0539610A1 (de) 1991-10-26 1991-10-26 Verfahren und Zusammensetzung zur Bestimmung der Immunologischen Aktivität von aktiven Substanzen enthaltende Lösungen
PCT/EP1992/002228 WO1993008470A1 (en) 1991-10-26 1992-09-28 Method and composition for determining the immunological activity of bioactive substances

Publications (1)

Publication Number Publication Date
SK44094A3 true SK44094A3 (en) 1995-03-08

Family

ID=8207282

Family Applications (1)

Application Number Title Priority Date Filing Date
SK440-94A SK44094A3 (en) 1991-10-26 1992-09-28 Method and composition for determining the immunological activity of bioactive substances

Country Status (23)

Country Link
US (1) US5543300A (de)
EP (2) EP0539610A1 (de)
JP (1) JPH07500905A (de)
AT (1) ATE153763T1 (de)
AU (1) AU678343B2 (de)
BG (1) BG61705B1 (de)
CA (1) CA2122131A1 (de)
CZ (1) CZ100494A3 (de)
DE (3) DE539610T1 (de)
DK (1) DK0609255T3 (de)
ES (1) ES2061424T3 (de)
FI (1) FI941920A0 (de)
GR (3) GR930300100T1 (de)
HK (1) HK1002610A1 (de)
HU (1) HU216863B (de)
LV (1) LV12140B (de)
NO (1) NO941444L (de)
PL (1) PL170592B1 (de)
RO (1) RO114837B1 (de)
RU (1) RU2125727C1 (de)
SG (1) SG72665A1 (de)
SK (1) SK44094A3 (de)
WO (1) WO1993008470A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19615470A1 (de) * 1996-04-19 1997-10-23 Heinz Beinio Körperpflegemittel und Verfahren zu seiner Herstellung
EP1115408B1 (de) * 1998-09-23 2006-01-25 Pfeinsmith Limited Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
GB0101973D0 (en) * 2001-01-25 2001-03-14 Statens Seruminstitut Improved in vitro diagnostic method of detecting a cell-mediated immune response
DE60304989T2 (de) * 2003-02-18 2007-03-29 Clinique La Prairie Research S.A. Zusammensetzungen enthaltend fötales Hämoglobin und bakterielles Endotoxin und fakultativ zusätzliche fötale Leberkomponenten
US7497947B2 (en) * 2004-04-14 2009-03-03 Embro Corporation Devices for water treatment
US7614340B2 (en) * 2007-02-09 2009-11-10 Honeywell International Inc. Composite piston housing for aircraft brakes
US9005449B2 (en) 2011-09-07 2015-04-14 Embro Corporation Use of moss to reduce disinfection by-products in water treated with disinfectants
US9795809B2 (en) 2013-12-23 2017-10-24 Embro Corporation Use of moss to improve dental health
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH636448A5 (en) * 1977-05-06 1983-05-31 Horst Veith Process for the determination of the effect of substances on constituents of the blood for the detection of infectious and immunological processes and composition for carrying it out
NZ214400A (en) * 1985-12-02 1989-05-29 Univ Otago Detecting infection in ruminant including conducting assay of mononuclear cell function
DE3782958D1 (de) * 1986-02-19 1993-01-21 Imreg Inc Verfahren und mittel zum pruefen eines immunsystems.
DE3779909T2 (de) * 1986-03-06 1993-01-07 Commw Scient Ind Res Org In-vitro-testverfahren zum nachweis zellulaerer immunresponsen.
US5096708A (en) * 1988-07-07 1992-03-17 Sven Gohla Medical preparation containing as active agent a component from thuja plants which comprises polysaccharides
ATE131859T1 (de) * 1991-03-16 1996-01-15 Torf Ets Verfahren zur kontinuierlichen extraction von torf und apparat zur durchführung dieses verfahrens

Also Published As

Publication number Publication date
EP0539610A1 (de) 1993-05-05
GR930300100T1 (de) 1993-10-29
NO941444D0 (no) 1994-04-21
DK0609255T3 (da) 1997-12-22
BG61705B1 (bg) 1998-03-31
HU9401185D0 (en) 1994-07-28
AU2650992A (en) 1993-05-21
WO1993008470A1 (en) 1993-04-29
US5543300A (en) 1996-08-06
CZ100494A3 (en) 1994-11-16
DE609255T1 (de) 1995-06-14
JPH07500905A (ja) 1995-01-26
EP0609255B1 (de) 1997-05-28
DE69220078D1 (de) 1997-07-03
GR940300077T1 (en) 1994-11-30
EP0609255A1 (de) 1994-08-10
LV12140A (lv) 1998-09-20
ATE153763T1 (de) 1997-06-15
HU216863B (hu) 1999-09-28
ES2061424T3 (es) 1997-10-01
DE69220078T2 (de) 1997-12-04
BG98720A (bg) 1995-07-28
RU2125727C1 (ru) 1999-01-27
RU94022481A (ru) 1996-09-27
HK1002610A1 (en) 1998-09-04
CA2122131A1 (en) 1993-04-29
LV12140B (lv) 1998-12-20
AU678343B2 (en) 1997-05-29
NO941444L (no) 1994-06-16
FI941920A (fi) 1994-04-25
DE539610T1 (de) 1993-12-16
PL170592B1 (en) 1997-01-31
HUT69990A (en) 1995-09-28
SG72665A1 (en) 2000-05-23
GR3024457T3 (en) 1997-11-28
ES2061424T1 (es) 1994-12-16
FI941920A0 (fi) 1994-04-25
RO114837B1 (ro) 1999-07-30

Similar Documents

Publication Publication Date Title
Ytterberg et al. Serum interferon levels in patients with systemic lupus erythematosus
Arneborn et al. T-lymphocyte subpopulations in relation to immunosuppression in measles and varicella
Stuart et al. Evidence for cell-mediated immunity to collagen in progressive systemic sclerosis
Niemialtowski et al. Predominance of Th1 cells in ocular tissues during herpetic stromal keratitis.
Valle et al. Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons
Friedman et al. Stimulation of interferon production in human lymphocytes by mitogens
Smith et al. Studies of an inhibitor of DNA synthesis and a nonspecific mitogen elaborated by human lymphoblasts.
Koff et al. Neuroendocrine hormones suppress macrophage-mediated lysis of herpes simplex virus-infected cells.
Torseth et al. Significance of local γ interferon in recurrent herpes simplex infection
Nathan Interferon-gamma and macrophage activation in cell-mediated immunity
SK44094A3 (en) Method and composition for determining the immunological activity of bioactive substances
Hill et al. Failure to demonstrate circulating interferon during incubation period and acute stage of transfusion-associated hepatitis
US5707814A (en) CD8+ cell antiviral factor
Argov et al. Defective natural killing activity but retention of lymphocyte-mediated antibody-dependent cellular cytotoxicity in patients with the X-linked lymphoproliferative syndrome
Wallace et al. Evidence for Clostridium perfringens enterotoxin (CPE) inducing a mitogenic and cytokine response in vitro and a cytokine response in vivo
JPH01110633A (ja) 肝細胞刺激因子
Jonsson et al. Elevated serum interferon levels in patients with Bell's palsy
Turco et al. Comparison of the properties of antirickettsial activity and interferon in mouse lymphokines
Chadha et al. Interferons and interferon inhibitory activity in disease and therapy
Aboagye-Mathiesen et al. Production of interferons in human placental trophoblast subpopulations and their possible roles in pregnancy.
Ingimarsson et al. Immune Reactions and Long‐Term Therapy with Human Leukocyte Interferon
US5565549A (en) CD8+ cell antiviral factor
US5580769A (en) CD8+ cell antiviral factor
Potts et al. Some tetracycline drugs suppress mitogen‐stimulated lymphocyte growth but others do not.
CA2300792A1 (en) An agent for increasing chemokine production